Association of clinical response and quality of life with long-term survival in CheckMate 227
In a recent presentation, Prof Dr Julie Brahmer, a medical oncologist at the Johns Hopkins Kimmel Cancer Center in Baltimore, MD, USA, analyzed the CheckMate 227 study. The study examined the effectiveness of first-line treatment with nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer. The results indicate that there is a potential link between tumour response, health-related quality of life improvement at six months, and long-term efficacy benefits of the treatment.
With the educational support of:
